Karyopharm Therapeutics Inc. announced that several abstracts that include selinexor data in myelofibrosis (MF) have been selected for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 9-12, 2023, in San Diego, CA. The data include an oral presentation featuring long-term efficacy results from the Phase 1 open-label, dose-escalation study of selinexor in combination with rxolitinib in patients with treatment-nave MF. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high unmet need cancer indications, including in endometrial cancer and myelofibrosis.